Pfizer: begins new study in Covid-19
(CercleFinance.com) - Pfizer has announced the start of the Phase 2/3 EPIC-PEP study to evaluate its novel investigational oral antiviral candidate PF-07321332, co-administered with low-dose ritonavir, for the prevention of the Covid-19 infection.
The trial is part of a global clinical research program and is recruiting people who are at least 18 years old who live in the same household as someone with confirmed symptomatic SARS-CoV-2 infection.
"PF-07321332 has been specifically designed to be administered orally, so that it can potentially be administered at the first sign of infection with, or exposure to, SARS-CoV-2, without requiring patients to be hospitalized," the healthcare giant said.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The trial is part of a global clinical research program and is recruiting people who are at least 18 years old who live in the same household as someone with confirmed symptomatic SARS-CoV-2 infection.
"PF-07321332 has been specifically designed to be administered orally, so that it can potentially be administered at the first sign of infection with, or exposure to, SARS-CoV-2, without requiring patients to be hospitalized," the healthcare giant said.
Copyright (c) 2021 CercleFinance.com. All rights reserved.